Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | RORA | P35398 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7305582 | 0.95 | HTR1A (0.50) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL7649804 | 0.94 | HTR1A (0.49) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL11010372 | 0.90 | PARP1 (0.52) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL6028786 | 0.84 | PGR (0.60) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL6295463 | 0.84 | PARP1 (0.50) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL29528989 | 0.84 | PGR (0.60) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL10827376 | 0.84 | PARP1 (0.50) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL11009779 | 0.84 | ALDH1A1 (0.60) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL7650175 | 0.83 | PARP1 (0.50) | PARP1DAOHTR1ADRD2HTR2A | |
| SCHEMBL7750879 | 0.83 | PGR (0.55) | PARP1DAOHTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9255080-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-09 | — | — | US | disclosed |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-8623884-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| EP-1763523-B1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120065216-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2012-03-15 | — | — | US | disclosed |
| US-8080557-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2008-02-14 | — | — | US | disclosed |
| EP-1763523-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006003148-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| US-6407116-B1 | 2,4-DIOXO-1,2,3,4-TETRAHYDROQUINAZOLINE DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES, AND ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1026160-A1 | NITROGENOUS FUSED-RING COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME, AND DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
| US-4680296-A | ANTIALLERGENS, ANTIPRUITIC AGENTS | SYNTHELABO (FR) | 1987-07-14 | — | — | US | disclosed |
| US-4522945-A | SEROTONINE ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-11 | — | — | US | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
| US-4335127-A | POTENT SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | disclosed |
| EP-0013612-A2 | (Piperidinylalkyl)quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885DAO 4656/4885HTR1A 762/4885 |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | PARP1, PARP2, PARP3 | PARP1 1/4885DAO 4656/4885HTR1A 762/4885 |
| US-20120065216-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885DAO 4656/4885HTR1A 762/4885 |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885DAO 4656/4885HTR1A 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.